Co-Diagnostics

Co-Diagnostics ROIC

The Return on Invested Capital (ROIC) of Co-Diagnostics (CODX) as of Oct 29, 2026 is -214.48 %. In the previous year, Return on Invested Capital (ROIC) was -66.66 % — a change of 221.75% (lower).

ROIC

-214.48 %

YoY

221.75%

Last updated:

Return on Invested Capital (ROIC) of Co-Diagnostics is 2025 -214.48 % . Return on Invested Capital (ROIC) of Co-Diagnostics was 2024 -66.66 % . It decreases by 221.75% lower compared to the previous year.

The Co-Diagnostics ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-738.06 USD
Jan 1, 2019
-356.63 USD
Jan 1, 2020
63.69 USD
Jan 1, 2021
26.08 USD
Jan 1, 2022
-12.40 USD
Jan 1, 2023
-39.70 USD
Jan 1, 2024
-66.66 USD
Jan 1, 2025
-214.48 USD
The Co-Diagnostics ROIC history
YEARROICYoY
-214.48 %+221.75%
-66.66 %+67.92%
-39.70 %+220.27%
-12.40 %-147.52%
26.08 %-59.05%
63.69 %-117.86%
-356.63 %-51.68%
-738.06 %+308.37%
-180.73 %-62.56%
-482.79 %-132.10%
1,504.05 %-298.93%
-756.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Return on Invested Capital (ROIC) of Co-Diagnostics is -214.48 % in 2025.

Return on Invested Capital (ROIC) of Co-Diagnostics changed from -66.66 % to -214.48 %, representing a 221.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Co-Diagnostics

All Key Metrics — Co-Diagnostics